NON-SMALL CELL LUNG CANCER

This study tested a new drug, AZD3759, against standard treatments for people with advanced lung cancer that has spread to the brain. The drug is designed to better reach and attack cancer cells in the brain. The trial involved 492 adults and found that AZD3759 helped keep the ca…

This study tested whether giving focused treatments (like heat or freezing) to cancer spots in the body can help control advanced lung cancer that has spread. The approach uses a blood test to find tiny bits of cancer DNA (minimal residual disease) and treats when levels rise. 37…

This study tested a combination of two drugs, tucidinostat and tislelizumab, as the first treatment for people with a certain type of advanced lung cancer (non-small cell lung cancer that is PD-L1 positive). The trial involved 118 adults who had not received prior cancer therapy …

This study tested a new drug called tiragolumab combined with atezolizumab in 135 people with advanced non-small cell lung cancer who had not received prior treatment. The goal was to see if the combination shrank tumors or slowed cancer growth better than atezolizumab alone. Par…

This study looked at people with a certain genetic type of advanced lung cancer (KRAS G12C) who had a small amount of cancer DNA still in their blood after initial treatment. Researchers wanted to see if switching to a targeted drug called sotorasib could control the cancer longe…

This study tested a combination of two drugs (ningetinib and gefitinib) in 108 people with advanced non-small cell lung cancer whose tumors had a specific gene change (EGFR mutation) but not another (T790M), and whose cancer had stopped responding to standard targeted therapy. Th…

This study tested whether adding the drug custirsen to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. It included 664 adults whose cancer had spread and who had already tried one prior treatment. The main goal was to compare o…

This study tested whether combining two drugs, brentuximab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma, lung cancer, or head and neck cancer that has spread. The trial included 161 participants whose cancer had not responded to prior treatments. …

This early-phase trial tested injecting the chemotherapy drug cisplatin directly into lung tumors during a bronchoscopy procedure. Six adults with early-stage, resectable non-small cell lung cancer participated to find the safest dose. The main goal was to identify any severe sid…

This study tested a combination of two drugs, RMC-4630 and sotorasib, in 47 adults with a specific kind of advanced lung cancer (KRASG12C mutation) that had stopped responding to standard treatments. The goal was to see if the combination could shrink tumors. The study is complet…

This study tested a drug called trastuzumab deruxtecan in 152 people with a specific type of advanced lung cancer (HER2-mutated) that had gotten worse after standard treatment. The main goal was to see if the drug could shrink tumors. The approach uses a targeted therapy to attac…

This study tested whether adding the immunotherapy drug serplulimab to standard chemotherapy before and after surgery helps people with stage II-IIIA non-small cell lung cancer. Thirty patients took part. The main goal was to see how many had a major response in their tumor tissu…

This study looked at 156 people with advanced non-small cell lung cancer that had come back after initial treatment. It compared a combination of two drugs (erlotinib and docetaxel) given in sequence versus docetaxel alone. The goal was to see if the combination could help keep t…

This early-phase trial tested whether adding L-NMMA to the immunotherapy drug pembrolizumab is safe for people with several types of advanced cancer. The idea is that L-NMMA may remove a brake on the immune system, helping pembrolizumab work better. Only 12 adults took part, and …

This early-phase study tested a new drug called BAY 2862789 in 45 people with advanced solid tumors, including a type of lung cancer. The drug works by activating the body's immune T-cells to fight cancer. The main goals were to check safety, find the best dose, and see how the d…

This study tested a combination of two targeted drugs, encorafenib and binimetinib, in 98 people with a specific type of advanced lung cancer (BRAFV600-mutant non-small cell lung cancer). The goal was to see if the drugs could shrink tumors. Participants had either not received p…

This study looked at how safe and effective Tabrecta is for people with a certain type of advanced lung cancer (MET exon 14 skipping mutation). It included 109 patients who took the drug and were followed for up to one year. The goal was to track side effects and how well the dru…

This early-phase study tested the safety of combining several cancer drugs (niraparib, TSR-022, bevacizumab, chemotherapy, and TSR-042) in 60 people with advanced or metastatic solid tumors. The goal was to find safe doses for each combination to use in later studies. Participant…

This study tested whether customizing chemotherapy based on two genetic markers (EGFR mutations and BRCA1 levels) improves outcomes for people with advanced lung adenocarcinoma. 153 patients received treatments matched to their tumor's genetic profile. The goal was to see if this…

This study tested a new drug called ensartinib (X-396) in 131 people with advanced solid tumors, including a type of lung cancer driven by an ALK gene change. The main goals were to find the safest dose and see if the drug could shrink tumors. Early results suggest it may help co…

This study tested whether combining the immunotherapy drug nivolumab with another drug (ipilimumab) or with standard chemotherapy could help people with advanced non-small cell lung cancer live longer without their cancer growing. About 2,700 patients who had not received prior t…

This trial tested several targeted drugs in people with non-small cell lung cancer whose tumors had specific genetic markers. The goal was to see if these drugs could shrink tumors or delay cancer growth. Over 400 participants received treatment matched to their cancer's genetic …

This early-stage study tested a new drug called GDC-1971 combined with standard treatments for advanced lung or colorectal cancer. The main goal was to check safety and find the right dose in 10 patients. It is a first step to see if this combination might help control these canc…

This study tested a new drug called gimistotug (BGB-A445) combined with other experimental drugs in 35 people with advanced non-small cell lung cancer who had already received standard treatments like immunotherapy and chemotherapy. The main goal was to see if the combination cou…

This study tested a new drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, or breast cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was completed, but res…

This study tested a combination of two drugs, atezolizumab and bevacizumab, as the first treatment for people with advanced non-squamous non-small cell lung cancer that has a high number of genetic mutations. The goal was to see if this drug pair could slow down cancer growth. Th…

This early-phase study tested a custom-made yeast vaccine designed to teach the immune system to recognize and attack leftover cancer cells. Five adults with different solid tumors (like colorectal, breast, or lung cancer) who had already completed curative treatment received the…

This early-phase study tested an experimental oral drug called JAB-3312 in 40 adults with advanced solid tumors (such as lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goal was to find a safe dose and understand side effects. Participa…

This study tested whether the immunotherapy drug pembrolizumab could help prevent lung cancer from coming back in people with early-stage non-small cell lung cancer (stages IB to IIIA) who had already had surgery and standard chemotherapy. About 1,177 participants received either…

This study tested a personalized approach to radiation therapy for people with stage III lung cancer that cannot be removed by surgery. During standard chemo-radiation, doctors used PET scans to see how the tumor was responding and adjusted the radiation dose to target stubborn a…

This study tested giving the immunotherapy drug tislelizumab, alone or with other treatments, before surgery for stage II to IIIA non-small cell lung cancer. The goal was to see if these treatments could shrink tumors and improve outcomes. 121 adults participated, and the main me…

This study tested a daily pill called sotorasib in 42 adults with advanced lung cancer that has a specific genetic change (KRAS G12C) and has not been treated yet. The goal was to see if the drug shrinks tumors and how safe it is. Participants received either a 960 mg or 240 mg d…

This study tested whether adding tiragolumab to the standard immunotherapy atezolizumab helps people with advanced non-small cell lung cancer (NSCLC) live longer without their cancer growing. About 620 adults with high PD-L1 levels who had not received prior treatment were random…

This study tested a combination of two drugs (NT-I7 and pembrolizumab) in 215 adults with advanced solid tumors that had come back or stopped responding to standard treatments. The goal was to find a safe dose and see if the combo could shrink tumors. The study also looked at imm…

This early-phase study tested a new drug called TPST-1495, alone or with pembrolizumab, in 89 people with advanced solid tumors (like colorectal, lung, or head and neck cancer) that had stopped responding to standard treatments. The main goal was to find the safest dose and check…

This study tested whether adding immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy before surgery helps people with early-stage non-small cell lung cancer. About 505 participants received either immunotherapy plus chemo or chemo alone before their tumor was …

This early-stage study tested a new drug called CHS-388 in 145 people with advanced solid tumors (like kidney, liver, or lung cancer) that had stopped responding to standard treatments. The drug works by blocking a protein called IL-27 to help the immune system fight cancer. The …

This study looked at whether giving palliative radiation to 2 to 5 tumor sites before starting standard immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer. Fifty adults with stage IV cancer and low PD-L1 levels took part. The goal was to see i…

This study tested a new way of giving radiation therapy (a mix of high and low doses) along with immunotherapy for people with advanced non-small cell lung cancer that does not have certain gene mutations. The goal was to see if this combination is safe and can help control the c…

This early-stage study tested an experimental drug called CTX-471, given alone or with another immunotherapy (pembrolizumab), in 100 adults with advanced solid tumors that had stopped responding to standard PD-1/PD-L1 inhibitors. The main goal was to check safety and find the rig…

This study tested a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy (paclitaxel) in 46 people with untreated advanced non-small cell lung cancer. The goal was to see if the combo could delay cancer growth and be safe. Results help guide future …

This early-stage study tested a new treatment for people with advanced non-small cell lung cancer that had grown or returned after standard therapy. Researchers took patients' own immune cells, modified them in a lab to recognize and attack cancer cells, and infused them back aft…

This study tested whether adding lenvatinib to the immunotherapy drug pembrolizumab helps people with advanced non-small cell lung cancer (NSCLC) who have not had prior treatment. Over 600 adults with tumors showing at least 1% PD-L1 took part. The goal was to see if the combinat…

This early-phase trial tested whether adding the drug pirfenidone to standard chemotherapy is safe and effective for people with advanced non-small cell lung cancer. 48 participants received the combination to find the best dose and see if tumors shrank. The goal was to control t…

This study looked at whether giving immunotherapy drugs (nivolumab alone or with ipilimumab) after standard chemoradiation can help people with stage III lung cancer that cannot be removed by surgery. About 105 participants were enrolled. The goal was to see if these treatments c…

This early-phase study tested a new antibody (BGB-A445) alone or with another drug (tislelizumab) in 204 people with advanced solid tumors, including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. While the treatment a…

This study tested whether giving a short course of radiation to one tumor site within two weeks of starting immunotherapy could help the immune system fight cancer better. It included 76 adults with advanced lung or head/neck cancers who were already eligible for standard immunot…

This study tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with stage IV non-small cell lung cancer live longer. About 719 patients who had not received prior treatment took part. The results showed that the combinati…

This study tested a new drug called DS-1062a in 137 adults with advanced or spreading non-small cell lung cancer that has certain gene changes. Participants had already tried targeted therapy and platinum chemotherapy without success. The main goal was to see if the drug could sh…

This study tested a combination of two drugs—pembrolizumab (an immunotherapy) and Imprime PGG (a yeast-based immune booster)—in 35 adults with advanced non-small cell lung cancer that had worsened after initial therapy. The goal was to see if the combo could shrink tumors or slow…

This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…

This study tested a drug called AZD9291 (osimertinib) in 171 people from Asia Pacific with advanced non-small cell lung cancer that had a specific gene mutation (T790M) and had stopped responding to earlier treatments. The main goal was to see how many patients had their tumors s…

This study tested whether adding a bronchoscopy-guided treatment to standard immunotherapy and chemotherapy helps people with advanced central non-small cell lung cancer. The trial included 33 adults whose cancer could not be surgically removed. The goal was to see if the triple …

This study tested whether giving lung cancer treatments based on the genetic details of a person's tumor could help control the disease. It included 50 adults with advanced non-small cell lung cancer. Some received immunotherapy (atezolizumab) alone or with chemotherapy, while ot…

This study tested a combination of two drugs, nivolumab and ALT-803, in 67 people with advanced non-small cell lung cancer that had already been treated. The goal was to see if the combination was safe and how many patients' tumors shrank. The approach aims to boost the immune sy…

This early-stage study tested whether adding PB101 (a patient's own immune cells) to standard targeted therapy (EGFR-TKI) is safe for people with advanced EGFR-mutated non-small cell lung cancer. Eight adults with stage IIIB/IV disease received the combination. The main goal was …

This trial tested a new drug called AK112 in 108 people with advanced non-small cell lung cancer (stage IIIB/C or IV) whose tumors had a PD-L1 score of 1% or higher. The drug is a bispecific antibody that targets both PD-1 and VEGF to help the immune system fight cancer and block…

This large Phase 3 study tested adding the immunotherapy drug cemiplimab to standard chemotherapy for people with advanced non-small cell lung cancer. About 789 participants received either the combination or chemo alone. The goal was to see if the combo helped people live longer…

This study tested an experimental drug called BA3011, given alone or with an immunotherapy (PD-1 inhibitor), in 85 adults with advanced non-small cell lung cancer that had stopped responding to prior treatments. The goal was to see if the drug could shrink tumors or slow the canc…

This early-phase study tested the drug RAD001 (everolimus) combined with radiation therapy in 26 people with advanced non-small cell lung cancer that could not be removed by surgery. The main goal was to find safe doses and check side effects. Participants took RAD001 weekly or d…

This early-phase study tested whether adding copanlisib to the immunotherapy durvalumab could help patients with stage III non-small cell lung cancer that cannot be removed by surgery. Eleven patients who had already received chemotherapy and radiation took part. The main goal wa…

This study tested whether a shot under the skin (subcutaneous) of the immunotherapy drug atezolizumab works as well as the standard IV drip for people with advanced non-small cell lung cancer. About 438 patients who had already tried chemotherapy took part. The goal was to see if…

This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had minimal residual disease (small amounts of cancer left after standard treatment). The goal was to see if t…

This study tested whether adding the experimental drug OSI-906 to the standard targeted therapy erlotinib (Tarceva) helps people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. 88 participants who had not received prior chemotherapy were randomly …

This study tested an immunotherapy drug called durvalumab for people with advanced non-small cell lung cancer that had worsened despite previous chemotherapy treatments. Researchers enrolled 446 patients to see if the drug could shrink tumors and extend survival. The treatment wa…

This study tested whether a new blood test (liquid biopsy) can accurately find cancer biomarkers in patients with head and neck, lung, or skin cancer. 135 adults with advanced cancer provided blood and tumor tissue samples. The goal was to see if the blood test works as well as t…

This study looked at whether a blood test can find gene changes in people with advanced lung cancer. 22 adults with advanced non-small cell lung cancer gave a blood sample. The test was compared to standard tissue tests to see if it works well enough for everyday use.

This study tested a special way of taking PET scans that accounts for breathing movements. The goal was to see if it could better detect small lung nodules in 103 patients with lung cancer or COPD. Participants had a standard PET scan plus an extra 10-minute scan while following …

This study looked at whether a special supplement with essential amino acids could help people with advanced lung cancer maintain muscle and prevent weight loss. 41 patients took part. The goal was to see if the supplement could improve how the body builds protein, which is impor…

This study tested whether people with non-small cell lung cancer prefer getting the drug atezolizumab as a quick shot under the skin (subcutaneous) or as a longer IV drip into a vein. About 179 patients tried both methods and reported which they liked better. The goal was to see …

This study tested whether adding structured family support to standard palliative care helps people with advanced lung cancer feel better and make clearer decisions. 110 adults were split into two groups: one received routine nursing, the other added family involvement, counselin…

This study looked at whether a home-based exercise program can help people with non-small cell lung cancer manage severe tiredness after surgery. 235 adults took part. The program was designed to be simple, safe, and low-cost. The goal was to reduce fatigue and improve quality of…

This study tested a faster radiation treatment called Quad Shot for people with advanced lung cancer who are also on other cancer drugs. The goal was to see if giving radiation in fewer, more intense sessions is safe and doesn't interfere with their regular treatment. 41 patients…

This study tested two different radiotherapy schedules for people with advanced non-small cell lung cancer. One group received the standard 6-week treatment, while the other got a shorter 4-week course based on PET scans. The main goal was to see which schedule caused fewer sever…

This study tested a new bendable surgical tool (SurgeoFlex Grasp) versus a standard rigid tool for keyhole lung cancer surgery in 100 adults with early-stage non-small cell lung cancer. The goal was to see if the flexible tool makes lymph node removal faster, reduces instrument c…

This study looked at whether a special type of PET scan (parametric imaging) can better predict if non-small cell lung cancer will come back within a year after treatment. Researchers compared this new scan method to the standard PET scan in 40 patients who had chemotherapy and r…

This study looked at 40 adults with advanced non-small cell lung cancer whose tumors have high PD-L1 levels. Researchers used PET scans after the first dose of the immunotherapy drug pembrolizumab to see if early changes in tumor sugar uptake could predict whether the cancer woul…

This study looked at how a lung cancer drug (AZD9291) affects the way the body processes simvastatin, a common cholesterol medicine. It involved 52 adults with a specific type of advanced lung cancer (EGFR mutation-positive NSCLC) whose disease had worsened after previous treatme…

This study looked at blood samples from 50 people with a specific type of lung cancer (ALK-positive) whose cancer had stopped responding to treatment. The goal was to find genetic changes in the blood that explain drug resistance, so doctors can choose the next treatment more eff…

This study reviewed medical records of 350 Australian adults with advanced EGFR-mutant non-small cell lung cancer to see how they responded to the drug osimertinib, either as their first or second treatment. Researchers tracked how long patients stayed on the drug and their overa…

This study tracked 25 adults with non-small-cell lung cancer who were taking the drug osimertinib. Researchers measured their weight, muscle mass, and diet to understand how nutrition and muscle loss (sarcopenia) relate to treatment side effects and quality of life. The goal was …

This study looked back at medical records of 240 adults in Poland with advanced non-small cell lung cancer. They were given a combination of two immunotherapy drugs plus chemotherapy as their first treatment. The goal was to see how well the treatment worked and what side effects…

This study looked at whether adding a simple blood test (liquid biopsy) to the standard tissue test could help find more gene changes (EGFR mutations) in people with advanced lung cancer. Over 500 patients who had not yet been treated provided both blood and tissue samples. The g…

This study examined lung cancer tissue from 56 patients to look for specific protein pieces called Met receptor fragments. Researchers used a technique called Western blot to compare tumor tissue with healthy tissue. The goal was to understand how these fragments might relate to …

This study looked at whether people with advanced cancers (melanoma, kidney, or lung cancer) receiving first-line immunotherapy can successfully collect small blood samples at home using a finger-prick method. 24 patients participated, and the goal was to see if home testing is p…

This study aimed to find biological markers in the blood and tumors that could predict how well patients with advanced non-small cell lung cancer respond to the immunotherapy drug atezolizumab. Researchers analyzed immune cells, genetics, and microbiomes from 100 participants. Th…

This study looked at using simple blood tests (liquid biopsies) to find a specific resistance mutation called T790M in 70 patients with advanced lung cancer in Tunisia. The goal was to see how often the mutation appears when the cancer stops responding to initial targeted therapy…

This study looked at 62 people with ALK-positive lung cancer whose tumors had stopped responding to newer targeted drugs. Instead of a tissue biopsy, researchers used a simple blood test (liquid biopsy) to find genetic changes that cause drug resistance. The goal was to better un…

This study looked at 212 adults with advanced non-small cell lung cancer who received the immunotherapy drug nivolumab after chemotherapy. Researchers tracked how many patients were still alive 1, 2, and 3 years after starting treatment. The goal was to see how well the drug work…

This study looked at 60 people with advanced lung cancer who were receiving immunotherapy. Researchers checked if taking beta-blockers (a common blood pressure medicine) at the same time changed how well the cancer treatment worked. They compared tumor shrinkage, time until cance…

This study looked at health records from nearly 5,000 people with non-small cell lung cancer to see if they could recreate the results of a famous clinical trial (FLAURA). The goal was to learn when real-world data can be trusted for research. No new treatments were given—just an…

This study explored whether emotional distress before treatment and certain blood markers (like inflammation levels) can predict how well immunotherapy works in people with advanced lung or gastroesophageal cancer. Researchers followed 196 patients who had not received prior trea…

This study looked at whether a test using 6 different markers from tumor tissue can predict how well people with advanced non-small cell lung cancer respond to a combination of immunotherapy (pembrolizumab) and chemotherapy. The goal was to see if this test is better than the cur…

This study looked back at medical records of 833 people with advanced non-small cell lung cancer to understand what treatments they received and how they fared. Researchers collected data from doctor surveys across multiple countries. The goal was to learn about real-world treatm…

This study created a regional database of 518 adults with non-small cell lung cancer who had a gene mutation. Researchers collected detailed clinical information, such as age, smoking history, and cancer stage, to see how these factors relate to different mutations. The goal was …

This study looked at the safety of the drug sotorasib in 102 Chinese adults with a specific type of advanced lung cancer (KRAS G12C-mutated NSCLC). Researchers tracked side effects like liver problems, lung inflammation, and kidney issues. The goal was to understand real-world ri…

This study looked at how a new cancer drug, MK-1084, affects the levels of two other drugs (midazolam and digoxin) in the body. 28 healthy adults took these drugs with and without MK-1084 to see if there were any changes. The goal was to understand potential drug interactions, no…

This study tracked 1,290 people with non-small cell lung cancer who were already taking the drug Lorbrena. The goal was to learn more about side effects, especially brain and liver problems. Researchers wanted to see what factors might increase these risks. The study did not test…